Product nameAnti-EIF2B1 antibody
See all EIF2B1 primary antibodies
DescriptionRabbit polyclonal to EIF2B1
Tested applicationsSuitable for: IHC-P, WBmore details
Species reactivityReacts with: Mouse, Human
Predicted to work with: Rat, Cow, Cynomolgus monkey, Orangutan
Recombinant full length protein corresponding to Human EIF2B1 aa 1-305.
MDDKELIEYFKSQMKEDPDMASAVAAIRTLLEFLKRDKGETIQGLRANLT SAIETLCGVDSSVAVSSGGELFLRFISLASLEYSDYSKCKKIMIERGELF LRRISLSRNKIADLCHTFIKDGATILTHAYSRVVLRVLEAAVAAKKRFSV YVTESQPDLSGKKMAKALCHLNVPVTVVLDAAVGYIMEKADLVIVGAEGV VENGGIINKIGTNQMAVCAKAQNKPFYVVAESFKFVRLFPLNQQDVPDKF KYKADTLKVAQTGQDLKEEHPWVDYTAPSLITLLFTDLGVLTPSAVSDEL IKLYL
Database link: Q14232
- WB: MCF7, K562, Jurkat and A431 whole cell lysates; Mouse liver and brain tissue lysates. IHC-P: Human prostate cancer and breast cancer tissues.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 7.3
Preservative: 0.02% Sodium azide
Constituents: PBS, 50% Glycerol
Concentration information loading...
PurityImmunogen affinity purified
- Mouse liver tissue lysate - total protein (ab29301)
- MCF7 whole cell lysate (ab29537)
- Jurkat whole cell lysate (ab30128)
- A431 whole cell lysate (ab30132)
- Mouse brain tissue lysate - total protein (ab30151)
- MCF7 whole cell lysate (ab3871)
- Mouse brain tissue lysate - total protein (ab4022)
- Jurkat whole cell lysate (ab7899)
- A431 whole cell lysate (ab7909)
- K562 whole cell lysate (ab7911)
Our Abpromise guarantee covers the use of ab229704 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IHC-P||1/20 - 1/200.|
|WB||1/1000 - 1/5000. Predicted molecular weight: 34 kDa.|
FunctionCatalyzes the exchange of eukaryotic initiation factor 2-bound GDP for GTP.
Involvement in diseaseDefects in EIF2B1 are a cause of leukodystrophy with vanishing white matter (VWM) [MIM:603896]. VWM is a leukodystrophy that occurs mainly in children. Neurological signs include progressive cerebellar ataxia, spasticity, inconstant optic atrophy and relatively preserved mental abilities. The disease is chronic-progressive with, in most individuals, additional episodes of rapid deterioration following febrile infections or minor head trauma. While childhood onset is the most common form of the disorder, some severe forms are apparent at birth. A severe, early-onset form seen among the Cree and Chippewayan populations of Quebec and Manitoba is called Cree leukoencephalopathy. Milder forms may not become evident until adolescence or adulthood. Some females with milder forms of the disease who survive to adolescence exhibit ovarian dysfunction. This variant of the disorder is called ovarioleukodystrophy.
Sequence similaritiesBelongs to the eIF-2B alpha/beta/delta subunits family.
- Information by UniProt
- EI2BA_HUMAN antibody
- eIF-2B GDP-GTP exchange factor subunit alpha antibody
- EIF2B antibody
All lanes : Anti-EIF2B1 antibody (ab229704) at 1/1000 dilution
Lane 1 : MCF7 (human breast adenocarcinoma cell line) whole cell lysate
Lane 2 : K562 (human chronic myelogenous leukemia cell line from bone marrow ) whole cell lysate
Lane 3 : Mouse liver tissue lysate
Lane 4 : Mouse brain tissue lysate
Lane 5 : Jurkat (human T cell leukemia cell line from peripheral blood) whole cell lysate
Lane 6 : A431 (human epidermoid carcinoma cell line) whole cell lysate
All lanes : Goat anti-rabbit IgG at 1/10000 dilution
Predicted band size: 34 kDa
Observed band size: 34 kDa
Paraffin-embedded human prostate cancer tissue stained for EIF2B1 using ab229704 at 1/100 dilution in immunohistochemical analysis.
Paraffin-embedded human breast cancer tissue stained for EIF2B1 using ab229704 at 1/100 dilution in immunohistochemical analysis.
ab229704 has not yet been referenced specifically in any publications.